Lupin Launches New Generic Drug In US Market

MUMBAI, (IANS) – Pharma major Lupin Limited has said that it has launched Mirabegron extended-release tablets, 25 mg, in the US market, after having received approval from the Food and Drug Administration.

Mirabegron Extended-Release Tablets, 25 mg is a generic equivalent of Myrbetriq®Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc, the Mumbai-headquartered company said.

Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of $1,019 million in the US, market, according to Lupin.

The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific, Latin America, Europe, and Middle East regions, the statement added.